ReviewAnnals of laboratory medicine2017
Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations.
Review in Annals of laboratory medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Malnutrition assessment methods in adult patients with tuberculosis: a systematic review.BMJ open · 2021Pooled it
- Improvement of Nutritional Status among Tuberculosis Patients byBioMed research international · 2020Trial
- Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis.International journal of mycobacteriologyTrial
- Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB).Emerging microbes & infections · 2025Article
- Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance.Pharmaceutics · 2025Review
- Article
- A Longitudinal Prospective Study of Active Tuberculosis Among Patients in Tétouan, Morocco.Cureus · 2025Article
- MEAN DIFFERENCE OF ZINC AND SELENIUM LEVELS AND TUBERCULOSIS OUTCOMES IN CHILDREN RECEIVING TREATMENT IN INDONESIA.African journal of infectious diseases · 2025Article
- A mixed-methods study on healthcare workers' perceptions of treatment adherence among HIV-TB co-infected patients in a multi-disease prevention policy context.Frontiers in public health · 2025Article
- Determination ofPharmaceutics · 2024Article
- Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine.Molecules (Basel, Switzerland) · 2024Article
- Nutritional scores predict the prognosis of patients with pulmonary tuberculosis.Frontiers in nutrition · 2024Article
- Nutritional Indices Predict All Cause Mortality in Patients with Multi-/Rifampicin-Drug Resistant Tuberculosis.Infection and drug resistance · 2024Article
- Prevalence and prognostic significance of malnutrition risk in patients with tuberculous meningitis.Frontiers in public health · 2024Article
- New approach to rifampicin stability and first-line anti-tubercular drug pharmacokinetics by UPLC-MS/MS.Journal of pharmaceutical and biomedical analysis · 2023Article
- Improving Tuberculosis Medication Adherence: The Potential of Integrating Digital Technology and Health Belief Model.Tuberculosis and respiratory diseases · 2023Article
- The role ofFrontiers in cellular and infection microbiology · 2023Review
- The rs1801280 SNP is associated with non-small cell lung carcinoma by exhibiting a highly deleterious effect on N-acetyltransferase 2.Journal of cancer research and clinical oncology · 2023Article
- Review
- Prevalence and prognostic significance of malnutrition risk in patients with pulmonary tuberculosis: A hospital-based cohort study.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although tuberculosis is largely a curable disease, it remains a major cause of morbidity and mortality worldwide. Although the standard 6-month treatment regimen is highly effective for drug-susceptible tuberculosis, the use of multiple drugs over long periods of time can cause frequent adverse drug reactions. In addition, some patients with drug-susceptible tuberculosis do not respond adequately to treatment and develop treatment failure and drug resistance. Response to tuberculosis treatment could be affected by multiple factors associated with the host-pathogen interaction including genetic factors and the nutritional status of the host. These factors should be considered for effective tuberculosis control. Therefore, therapeutic drug monitoring (TDM), which is individualized drug dosing guided by serum drug concentrations during treatment, and pharmacogenetics-based personalized dosing guidelines of anti-tuberculosis drugs could reduce the incidence of adverse drug reactions and increase the likelihood of successful treatment outcomes. Moreover, assessment and management of comorbid conditions including nutritional status could improve anti-tuberculosis treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.